News

Cosmo places Santarus shares
Enlarge image

BusinessItaly

Cosmo places Santarus shares

14.05.2013 - Cosmo Pharmaceuticals' subsidiary Cosmo Technologies Ltd, has placed 4,250,000 Santarus shares in a secondary public offering to investors in the US.

After having placed 4,250,000 of its 7,878,544 Santarus shares to US investors, the sole bookrunner Jefferies LLC, exercised an option to purchase additional 637,500 Santarus shares at the same price.

The specialist for gastro-intestinal and skin disorders did not sell any shares and will not receive any proceeds from the offering. The transaction is expected to close on May 15, subject to satisfaction of customary closing conditions. The shares were originally purchased at an average price of € 1.77. Per year end 2012 each share was worth € 8.32.  

Cosmo’s proprietary clinical development pipeline specifically addresses treatments for IBD, such as ulcerative colitis and Crohn’s disease, and colon infections. Additionally, the company is developing a diagnostic tool for the detection of colon cancer and a new drug for the topical treatment of Acne, Alopecia and Hirsutism. Cosmo’s first product on the market is Lialda®/Mezavant®/Mesavancol®, a treatment for mild to moderate ulcerative colitis that is licensed globally to Giuliani and Shire Limited. Cosmo’s second product is Uceris™/Cortiment™, a steroid with low side effects that is indicated for ulcerative colitis patients that do not get relief when treated with 5-ASA’s, and which is licensed globally to Santarus and Ferring.

Cosmo’s proprietary MMX® technology is at the core of the company’s product pipeline and was developed through its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (facilities in Lainate, Italy. The technology of the young company is designed to targeted delivery of active ingredients in the intestines.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/cosmo-places-santarus-shares.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF2202.8%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR190.3%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.58 EUR-41.1%
  • 4SC1.09 EUR-40.1%

No liability assumed, Date: 16.09.2014